Company intelligence / Profile preview
Mosaic Therapeutics
Cambridge, Cambridgeshire, United Kingdommosaic-tx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has in-licensed two clinical-stage oncology programs from Astex Pharmaceuticals: ASTX029 (ERK1/2 inhibitor that completed Phase 2) and ASTX295 (MDM2 antagonist that completed Phase 1). Each compound has been studied in more than 100 patients and demonstrated differentiated safety profiles and single-agent activity[4].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculestargeted therapiescombination therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Astex Pharmaceuticals
Beyond the preview
Go deeper on Mosaic Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mosaic Therapeutics.